
ReproGLIO
ReproGLIO – Pioneer TF-based Reprogramming to Intercept Pediatric Malignant Entities
Overview
Pediatric brain tumors of glial origin are invariably lethal. These aggressive malignancies exhibit extensive inter-patient and intra-tumoral heterogeneity, with tumor cells existing in multiple dynamic epigenetic and transcriptional states. Current treatments remain ineffective, with most patients succumbing within two years after diagnosis. ReproGLIO aims to induce fate conversion of tumor cells into terminally differentiated, non-proliferative neurons by direct lineage reprogramming, as a novel strategy to restrain cell state transitions, restrict proliferation and invasion, and ultimately reduce tumor growth and mortality.

Project leader

Christophe Heinrich, head of the « Cellular Reprogramming in the Brain » team at the Centre de Recherche en Neurosciences de Lyon (CRNL), CNRS UMR5292, Inserm U1028, Lyon 1 University.
Direct lineage reprogramming within the brain (CRNL, Lyon)
Research team



Marie Castets (CRCL, Lyon)
Pediatric oncology and pediatric tumor modeling.
Rita Khoueiry (IARC, Lyon)
Brain tumor epigenetics.
Jean-Baptiste Alberge (Gustave Roussy, Paris)
Computational biology & bioinformatics.
Key objectives
Building on our previous achievements and uniquely combining complementary expertise, we follow a stepwise strategy spanning three integrated work packages:
- To reprogram tumor cells into neurons across the oncogenic trajectory in vitro
Using engineered pre-neoplastic models and patient-derived organoids across disease stages, we identify factors enabling efficient neuronal conversion of the distinct tumor cell states.
- To reconstruct and engineer cell fate trajectories during neuronal conversion of glioma cells
Using single-cell multiomics, we dissect the mechanistic basis of tumor-to-neuron conversion to:
- Map dynamic chromatin accessibility and transcriptional changes governing neuronal conversion
- Reconstruct reprogramming trajectories to identify permissive versus refractory tumor states
- Engineer optimized reprogramming strategies to convert resistant cell states into neurons.
- To uncover the therapeutic potential of tumor cell reprogramming in preclinical models
- Assess whether tumor-to-neuron reprogramming disrupts tumor growth, limits brain invasion, and improves survival
- Examine if forcing neuronal differentiation at pre-neoplastic stages prevents tumor development
Resources deployed
- Engineered pre-neoplastic models
- Patient-derived organoids
- Patient-derived xenograft models
- Single-cell multiomics
- Spatial transcriptomics
- Targeted CRISPR-based perturbations
- CRISPR-based targeted epigenome editing
Expected results
We expect to show that reprogramming glioma cells into stable, post mitotic neurons:
- reduces intratumoral phenotypic plasticity and silences malignant signatures
- reduces tumor growth and invasion patterns by locking cells into less aggressive states
- ultimately improves survival.
ReproGLIO will also reveal if forcing neuronal reprogramming of cells at pre-neoplastic stages prevents tumor development and enables disease interception.
Together, ReproGLIO will uncover the translational potential of tumor-to-neuron reprogramming as a transformative therapeutic strategy for pediatric brain cancer interception.
Les autres projets PEPR